|Over a week ago|
IsoRay, University of Cincinnati Physicians Company sign research agreement » 08:2906/1706/17/20
Isoray announced that it…
Isoray announced that it has entered into a research grant agreement with the University of Cincinnati Physicians Company for a study involving the treatment of recurrent head and neck cancers. University of Cincinnati Physicians Company is the multispecialty practice group for University of Cincinnati College of Medicine and UC Health. The planned trial will evaluate the safety and early effectiveness of the addition of pembrolizumab to the regimen of Cesium-131 with surgical resection. Pembrolizumab is a humanized antibody used in cancer immunotherapy. A total of 50 patients whose head and neck cancers have recurred and who are eligible for surgical resection are planned to be enrolled. The study, A Trial Combining Pembrolizumab and Cesium-131 Brachytherapy with Salvage Surgery in Head & Neck Squamous Cell Carcinoma, will be carried out under the direction of principal investigators Dr. Shuchi Gulati and Dr. Chad Zender at the University of Cincinnati Medical Center. There is potential for other centers to participate in the study. Cancers of the head and neck that recur following the usual primary treatment involving surgery and radiation are difficult to successfully treat. Recurrence rates of 50% that occur at two years are typical. The use of immunotherapy in this study in tandem with resection and Cesium-131 brachytherapy presents an attractive therapeutic concept. In this approach, the patient's immune system may assist in the clearing of disease sites outside the surgical and radiation fields. A previous multi-institutional study has provided evidence that the use of Cesium-131 with surgical resection is well-tolerated in the treatment of recurrent head and neck cancers.
|Over a month ago|
IsoRay announces results of ten-year study of Cesium-131 » 08:2906/0206/02/20
Isoray announced that the…
Isoray announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray's Cesium-131 internal radiation therapy. The observational study from the University of Pittsburgh School of Medicine followed a large group of patients for up to ten years. Using a biochemical endpoint, the data show the ten year success rates for treatment with Cesium-131 were 95.3% for patients in the low-risk category, 90.1% for patients in the intermediate-risk category and 56.6% for 97 high-risk patients. Patients with higher risk cancers were treated with external beam radiation therapy in addition to their Cesium-131 implant, while lower risk patients underwent only a Cesium-131 implant. Cesium-131 has the shortest half-life and highest energy of brachytherapy seeds commonly used in the treatment of prostate cancer. Cesium's energy is powerful, allowing it to aggressively attack the cancer being treated. Its shorter half-life means the radiation delivers its treatment dose faster, reducing other issues for the patient that can come from prolonged radiation exposure. The rapid resolution of side effects is an important advantage for patients, allowing them to return to their normal lives faster. Unlike external beam radiation, Cesium-131 internal radiation therapy is able to deliver a precise dosage and placement of Cesium-131 seeds, leaving healthy tissues and organs undamaged.
IsoRay price target raised to $1.75 from $1.40 at Ascendiant » 06:1805/1505/15/20
Ascendiant analyst Edward…
Ascendiant analyst Edward Woo raised the firm's price target on IsoRay to $1.75 from $1.40 and keeps a Buy rating on the shares. The company reported "strong" revenue growth in Q3 and continued progress in commercialization for its Cesium-131 as a radiation source to treat cancers makes the stock's risk/reward attractive, Woo tells investors in a research note.
IsoRay announces CMS approval for 64 Cesium-131 reimbursement billing codes » 16:3805/1205/12/20
Isoray announced that the…
Isoray announced that the Centers for Medicare and Medicaid Services, or CMS, has approved 64 ICD-10-PCS billing codes used for reimbursement of Cesium-131 for the hospital in-patient DRG setting. The codes allow hospitals to bill Medicare and other health insurers for specific surgical procedures that would benefit from the addition of Cesium-131. DRG or diagnostic related groups are designed for Medicare and other health insurers to set payment levels for hospital in-patient services. The 64 ICD-10-PCS codes are important for the growing surgical applications of Cesium-131 in treating a significant range of hard to treat cancers including brain, lung, head and neck, abdominal, breast, gynecological, pelvic, and colorectal cancers. The new codes take effect on October 1. Isoray is the world's only supplier of Cesium-131. Brachytherapy with Cesium-131 seeds is high energy with a short half-life. Cesium-131's energy is powerful, allowing it to attack the cancer being treated. Its short half-life means the radiation delivers its treatment dose quickly reducing other issues for the patient that can come from prolonged radiation exposure. Unlike external beam radiation, Cesium-131 internal radiation therapy is able to deliver a precise dosage and placement of Cesium-131 seeds avoiding healthy tissues and organs.
IsoRay reports Q3 EPS (1c), consensus 1c » 16:3205/1205/12/20
Reports Q3 revenue…
Reports Q3 revenue $2.88M, consensus $2.55M. The company's core prostate brachytherapy revenue grew 42% when compared to Q3 of 2019. Prostate brachytherapy represented 84% of total revenue for Q3 compared to 88% in the prior year comparable period. The majority of non-prostate brachytherapy revenue in the quarter was comprised of sales to treat brain cancer, including sales of GammaTile Therapy. Net new physician customer count for the twelve-month period ending March 31, 2020 increased 33% versus the prior year comparable period. Isoray CEO Lori Woods said, "We are very pleased with the considerable progress we continue to achieve and the accelerated growth we realized in the quarter ended March 31st. This quarter generated the top three single highest revenue months in the company's history. We believe this is an important indicator of enduring momentum and further advancement."
|Over a quarter ago|
IsoRay price target raised to $1.25 from 70c at H.C. Wainwright » 07:1002/1202/12/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for IsoRay to $1.25 from 70c and rieterates a Buy rating on the shares. The "soft" Q2 revenue likely resulted from stronger than expected seasonal effects, says the analyst, who believes IsoRay is likely to resume its strong growth trajectory in fiscal Q3. While IsoRay's core prostate brachytherapy business continue to make up the bulk of the company's total revenues, the next 12 months could represent a "breakout period" for the company's GammaTile technology, Ramakanth tells investors in a post-earnings research note.
IsoRay reports Q2 EPS (1c), consensus (1c) » 16:0702/1102/11/20
Reports Q2 revenue…
Reports Q2 revenue $2.21M, consensus $2.31M. Isoray CEO Lori Woods said, "We are pleased to announce another strong quarter of growth and progress. We see continued growth of market share this quarter and we find that particularly rewarding given that we believetopline growth would have been greater had it not been for the timing of the holidays at the end of the quarter. Clearly, our momentum is enduring as preliminary sales for the month of January 2020 increased about 45% versus December 2019 and about 30% versus January 2019. With our growing share of the core prostate market and the increasing use of Cesium Blu(TM) to treat other hard to treat cancers, we are excited about the prospects for expanding opportunities as we continue to evolve our position as an industry leader and innovator."
IsoRay collaborates with MIM Software for head, neck cancer treatment » 08:4102/0502/05/20
Isoray announced an…
Isoray announced an executed agreement with MIM Software to deliver a novel one-stop-provides-all program to treat head and neck cancer. The new offering bundles MIM's software technology and Isoray's industry leading Cesium Blu, also known as Cesium-131, brachytherapy expanding treatment options and access for physicians and patients. Cesium Blu brachytherapy delivers a highly targeted treatment to the site of the disease, preserving healthy tissue and organs. Bringing together Isoray's Cesium Blu brachytherapy seeds in mesh with MIM Software's powerful brachytherapy treatment planning software provides physicians with all the anatomical information they need to effectively place the Cesium Blu seeds exactly where they are needed to treat the patient's cancer. Available now, the inclusive offering streamlines adoption of both the Cesium Blu brachytherapy treatment and MIM's planning software to deliver an economically feasible option for facilities and physicians treating head and neck cancers.
IsoRay announces publication of data of Cesium-131 » 08:2909/1809/18/19
IsoRay reported a study…
IsoRay reported a study of the ten-year findings on the impact of Cesium-131 internal radiation therapy in treating a series of cancer patients. The peer reviewed publication, Long-term Biochemical Outcomes Using Cesium-131 in Prostate Brachytherapy, was recently made available on the website of BRACHYTHERAPY, an international multidisciplinary journal. The publication reported on a study of a series of 571 patients who were treated with Cesium-131 prostate brachytherapy at the Chicago Prostate Cancer Center by radiation oncologist Dr. Brian J. Moran. The overall group was composed of 55% low risk, 36% intermediate risk, and 9% high risk localized prostate cancer patients as defined by NCCN ) guidelines. The majority of patients were treated with a Cesium-131 implant only, while the remainder were treated with external beam or hormone therapy -- or both - added to the Cesium-131 implant in cases of higher risk disease. Long-term results were reported for this patient group at 5, 7, and 10 years, The overall biochemical success rate for the entire group of patients at ten years was 96.2%.
American Society for Radiation Oncology to hold annual meeting » 04:5509/1709/17/19
NVCR, RHHBY, SNY, SIEGY, TDY, VAR, HTHIY, GHDX, ESALY, EKTAY, BMY, BSX, BAYRY, AZN, ARAY, MRK, MDT, WTKWY, HOLX, ISR
2019 ASTRO Annual Meeting…
2019 ASTRO Annual Meeting will be held in Chicago on September 15-18.